Van beleggers
voor beleggers
Uitgebreid zoeken

Beurscodes, betekenis en hulp bij zoeken

Europa

AEX
Euronext Amsterdam
BRU
Euronext Brussels
PSE
Euronext Paris
LIS
Euronext Lissabon
CHX
CBOE Europe, grote(re) EU aandelen
NAV
Investment Funds (NAV)

Noord-Amerika

NYS
New York Stock Exchange
OTC
CBOE BZX Exchange (US)
TSE
Toronto Stock Exchange

Kunt u een instrument niet vinden?

Zoek dan via de zogenaamde ISIN code. Elk instrument, aandeel etc. heeft een unieke code.

Kies vervolgens - wanneer er meerdere resultaten zijn - de notering op de beurs van uw keuze.

Waar vind ik die ISIN code?

Google de naam van het instrument, aandeel etc. met de toevoeging 'ISIN'.

Als zoeken op ISIN code geen resultaten oplevert hebben wij het instrument of aandeel niet in onze koersendatabase.

desktop iconMarkt Monitor
Home  /  Forum  /  BioPharma  /  Immunoprecise Antibodies

Ontvang nu dagelijks onze kooptips!

word abonnee

BioPharma« Terug naar discussie overzicht

Immunoprecise Antibodies

10 Posts
| Omlaag ↓
  1. fly like an eagle 23 juli 2021 11:16
    ImmunoPrecise Antibodies Ltd.

    ImmunoPrecise is an innovation-driven technology platform company that supports its business partners in their quest to discover and develop novel antibodies against a broad range of classes of disease targets. The Company aims to transform the conventional multi-vendor antibody discovery model by providing a comprehensive suite of services tailored to optimize antibody genetic diversity and epitope coverage, to discover antibodies against rare and/or challenging epitopes. For further information, visit www.immunoprecise.com

    Bedrijf dat in Utrecht en Oss zit voorheen U-Protein Express en Modiquest. Winstgevend.
  5. fly like an eagle 2 augustus 2021 22:29
    Fiscal 2021 Financial Summary*

    Earned revenues of $17.9 million, a 27% increase which includes a sale through Talem of an internally generated therapeutic antibody for $1.2 million, core CRO business up 19%
    Research and development costs increased to $2.0 million from $446,280 in 2020 due to the extensive research work the Company is undertaking, including COVID-19 related research projects
    The Company recorded a net loss of $7.3 million during the year ended April 30, 2021, compared to $5.0 million in 2020
    Adjusted EBITDA** of $2.3 million as compared to $52,000 in 2020
    As of April 30, 2021, the Company held cash of $41.8 million
  6. fly like an eagle 9 oktober 2021 12:09
    VICTORIA, BRITISH COLUMBIA (CANADA) and CASTRES (FRANCE), October 07, 2021 – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (NASDAQ: IPA) (TSX VENTURE: IPA) and the Pierre Fabre pharmaceutical group announced today that IPA’s subsidiary, Talem Therapeutics LLC (“Talem”), and Pierre Fabre have entered a multi-year, multi-target research collaboration with the goal to discover and develop therapeutics antibodies for up to nine targets. This strategic collaboration is expected to help expand Talem’s portfolio of novel antibodies across oncology. It adds to the variety of diverse relationships that the IPA group of companies holds across the pharmaceutical and biotechnology sector.

    Under the research collaboration, scientists from both companies will work together and contribute their respective resources to discover and develop novel antibodies leveraging the IPA group’s antibody discovery technologies, such as B cell Select™ or Deep Display™ using wild-type and/or transgenic animals, available human libraries, as well as their signature “end-to-end” services. The antibodies developed in the research collaboration against the selected targets will be jointly owned by Talem and Pierre Fabre and, following the completion of each target specific research program, Pierre Fabre will have an option to obtain an exclusive worldwide license to Talem’s interest in those jointly discovered antibodies against that particular target, and Talem would be eligible to receive certain up-front and contingent downstream payments. In addition, if licensed, Pierre Fabre will be responsible for the preclinical and clinical development, as well as the commercialization of the jointly discovered antibodies.

    “Less than two years ago we started Talem Therapeutics to provide a unique partnering opportunity for companies to jointly seek the development of promising novel candidates,” stated Dr. Stefan Lang, Chief Business Officer of ImmunoPrecise. “We are very excited to join forces with Pierre Fabre, combining our advanced antibody technologies with their world-class expertise in immuno-oncology is a powerful strategic combination enabling the teams to jointly address life threatening human diseases.”
    “Drug discovery in immuno-oncology is a priority for Pierre Fabre. We are therefore very pleased to enter this multi-target research collaboration. Talem will provide us with its expertise and a variety of technology platforms to enable the discovery of therapeutic antibodies, towards a set of structurally diverse targets.” added Francesco Hofmann, Head of R&D at Pierre Fabre Medical Care.
  8. fly like an eagle 20 december 2021 15:17
    Victoria biotech company expects its multi-antibody cocktail therapy "will retain activity" against Omicron variant
    In its latest quarterly financial statement, Immunoprecise Antibodies reported a $5-million net loss on revenues of $4.7 million

    by Charlie Smith on December 13th, 2021 at 5:41 AM
  10. fly like an eagle 31 januari 2022 15:04
    31 Jan 2022, 13:02
    Immunotherapeutic PolyTope® from ImmunoPrecise (IPA) Potently Neutralizes the SARS-CoV-2 Omicron Variant – Moves Towards FDA/IND-Submission

    IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the “Company”) (NASDAQ: IPA) (TSXV: IPA) is pleased to announce the release of data demonstrating strong neutralizing potency of its PolyTope® TATX-03 antibody cocktail towards the SARS-CoV-2 Omicron variant (B.1.1.529) in in vitro pseudovirus assays. This first generation four antibody cocktail against SARS-CoV-2 was rationally designed to sustain efficacy against all SARS-CoV-2 strains and variants with the goal of protecting and treating all individuals. The Company believes that it possesses the only first-generation cocktail therapy against SARS-CoV-2 (first publicly announced 2020) that has been demonstrated to retain efficacy against every variant of concern to date through in vitro pseudovirus assays conducted with respect to such variants of concern. PolyTope TATX-03 is unique in its ability to engage multiple modes of action, facilitated through simultaneously targeting various non-overlapping epitopes on the spike trimer.
10 Posts
|Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord.

Direct naar Forum

Indices

AEX 873,01 -1,25%
EUR/USD 1,0627 +0,02%
FTSE 100 7.858,23 -1,35%
Germany40^ 17.775,80 -1,39%
Gold spot 2.370,14 -0,55%
NY-Nasdaq Composite 15.885,02 -1,79%

Stijgers

Avantium
+3,90%
VIVORY...
+1,88%
B&S Gr...
+1,70%
Kendrion
+1,45%
Fagron
+0,91%

Dalers

Arcelo...
-6,62%
Aperam
-6,40%
SBM Of...
-5,11%
ASMI
-2,95%
Van La...
-2,94%

Lees verder op het IEX netwerk Let op: Artikelen linken naar andere sites

Gesponsorde links

Meld u aan voor de dagelijkse Beursupdate

Dagelijks een update van het laatste beursnieuws en beleggingskansen in uw mailbox!